Decreased PCSK9 expression in human hepatocellular carcinoma

Mamatha Bhat, N. Skill, Victoria Marcus, Marc Deschenes, Xianming Tan, Jeanne Bouteaud, Sarita Negi, Zuhier Awan, Reid Aikin, Janet Kwan, Ramila Amre, Sebastien Tabaries, Mazen Hassanain, Nabil G. Seidah, Mary Maluccio, Peter Siegel, Peter Metrakos

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol uptake into hepatocytes and affects liver regeneration. Thus, we investigated whether PCSK9 expression is altered in HCC, influencing its ability to harness cholesterol metabolism. Methods: Thirty-nine patients undergoing partial hepatectomy or liver transplantation for HCC were consented for use of HCC tissue to construct a tissue microarray (TMA). The TMA was immunostained for PCSK9. Imagescope software was used to objectively determine staining, and assess for pathological and clinical correlations. PCSK9 and LDL receptor mRNA levels in flash-frozen HCC and adjacent liver tissue were determined by quantitative RT-PCR. Serum PCSK9 levels were determined by ELISA. Results: By immunohistochemistry, there was significantly lower expression of PCSK9 in HCC as compared to adjacent cirrhosis (p-value <0.0001, wilcoxon signed-rank test). Significantly greater staining of PCSK9 was present in cirrhosis compared to HCC (p value

Original languageEnglish (US)
Article number176
JournalBMC Gastroenterology
Volume15
Issue number1
DOIs
StatePublished - Dec 16 2015

Fingerprint

Hepatocellular Carcinoma
LDL Receptors
Fibrosis
Cholesterol
Staining and Labeling
Liver Regeneration
Hepatectomy
Nonparametric Statistics
Liver Transplantation
Hepatocytes
Software
Biomarkers
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Drug Therapy
Polymerase Chain Reaction
Messenger RNA
Liver
Serum
Neoplasms

Keywords

  • Hepatocellular carcinoma
  • PCSK9
  • Tumor metabolism

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bhat, M., Skill, N., Marcus, V., Deschenes, M., Tan, X., Bouteaud, J., ... Metrakos, P. (2015). Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterology, 15(1), [176]. https://doi.org/10.1186/s12876-015-0371-6

Decreased PCSK9 expression in human hepatocellular carcinoma. / Bhat, Mamatha; Skill, N.; Marcus, Victoria; Deschenes, Marc; Tan, Xianming; Bouteaud, Jeanne; Negi, Sarita; Awan, Zuhier; Aikin, Reid; Kwan, Janet; Amre, Ramila; Tabaries, Sebastien; Hassanain, Mazen; Seidah, Nabil G.; Maluccio, Mary; Siegel, Peter; Metrakos, Peter.

In: BMC Gastroenterology, Vol. 15, No. 1, 176, 16.12.2015.

Research output: Contribution to journalArticle

Bhat, M, Skill, N, Marcus, V, Deschenes, M, Tan, X, Bouteaud, J, Negi, S, Awan, Z, Aikin, R, Kwan, J, Amre, R, Tabaries, S, Hassanain, M, Seidah, NG, Maluccio, M, Siegel, P & Metrakos, P 2015, 'Decreased PCSK9 expression in human hepatocellular carcinoma', BMC Gastroenterology, vol. 15, no. 1, 176. https://doi.org/10.1186/s12876-015-0371-6
Bhat, Mamatha ; Skill, N. ; Marcus, Victoria ; Deschenes, Marc ; Tan, Xianming ; Bouteaud, Jeanne ; Negi, Sarita ; Awan, Zuhier ; Aikin, Reid ; Kwan, Janet ; Amre, Ramila ; Tabaries, Sebastien ; Hassanain, Mazen ; Seidah, Nabil G. ; Maluccio, Mary ; Siegel, Peter ; Metrakos, Peter. / Decreased PCSK9 expression in human hepatocellular carcinoma. In: BMC Gastroenterology. 2015 ; Vol. 15, No. 1.
@article{bfab557517fd4c68b23fc3c036975c3f,
title = "Decreased PCSK9 expression in human hepatocellular carcinoma",
abstract = "Background: The management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol uptake into hepatocytes and affects liver regeneration. Thus, we investigated whether PCSK9 expression is altered in HCC, influencing its ability to harness cholesterol metabolism. Methods: Thirty-nine patients undergoing partial hepatectomy or liver transplantation for HCC were consented for use of HCC tissue to construct a tissue microarray (TMA). The TMA was immunostained for PCSK9. Imagescope software was used to objectively determine staining, and assess for pathological and clinical correlations. PCSK9 and LDL receptor mRNA levels in flash-frozen HCC and adjacent liver tissue were determined by quantitative RT-PCR. Serum PCSK9 levels were determined by ELISA. Results: By immunohistochemistry, there was significantly lower expression of PCSK9 in HCC as compared to adjacent cirrhosis (p-value <0.0001, wilcoxon signed-rank test). Significantly greater staining of PCSK9 was present in cirrhosis compared to HCC (p value",
keywords = "Hepatocellular carcinoma, PCSK9, Tumor metabolism",
author = "Mamatha Bhat and N. Skill and Victoria Marcus and Marc Deschenes and Xianming Tan and Jeanne Bouteaud and Sarita Negi and Zuhier Awan and Reid Aikin and Janet Kwan and Ramila Amre and Sebastien Tabaries and Mazen Hassanain and Seidah, {Nabil G.} and Mary Maluccio and Peter Siegel and Peter Metrakos",
year = "2015",
month = "12",
day = "16",
doi = "10.1186/s12876-015-0371-6",
language = "English (US)",
volume = "15",
journal = "BMC Gastroenterology",
issn = "1471-230X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Decreased PCSK9 expression in human hepatocellular carcinoma

AU - Bhat, Mamatha

AU - Skill, N.

AU - Marcus, Victoria

AU - Deschenes, Marc

AU - Tan, Xianming

AU - Bouteaud, Jeanne

AU - Negi, Sarita

AU - Awan, Zuhier

AU - Aikin, Reid

AU - Kwan, Janet

AU - Amre, Ramila

AU - Tabaries, Sebastien

AU - Hassanain, Mazen

AU - Seidah, Nabil G.

AU - Maluccio, Mary

AU - Siegel, Peter

AU - Metrakos, Peter

PY - 2015/12/16

Y1 - 2015/12/16

N2 - Background: The management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol uptake into hepatocytes and affects liver regeneration. Thus, we investigated whether PCSK9 expression is altered in HCC, influencing its ability to harness cholesterol metabolism. Methods: Thirty-nine patients undergoing partial hepatectomy or liver transplantation for HCC were consented for use of HCC tissue to construct a tissue microarray (TMA). The TMA was immunostained for PCSK9. Imagescope software was used to objectively determine staining, and assess for pathological and clinical correlations. PCSK9 and LDL receptor mRNA levels in flash-frozen HCC and adjacent liver tissue were determined by quantitative RT-PCR. Serum PCSK9 levels were determined by ELISA. Results: By immunohistochemistry, there was significantly lower expression of PCSK9 in HCC as compared to adjacent cirrhosis (p-value <0.0001, wilcoxon signed-rank test). Significantly greater staining of PCSK9 was present in cirrhosis compared to HCC (p value

AB - Background: The management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol uptake into hepatocytes and affects liver regeneration. Thus, we investigated whether PCSK9 expression is altered in HCC, influencing its ability to harness cholesterol metabolism. Methods: Thirty-nine patients undergoing partial hepatectomy or liver transplantation for HCC were consented for use of HCC tissue to construct a tissue microarray (TMA). The TMA was immunostained for PCSK9. Imagescope software was used to objectively determine staining, and assess for pathological and clinical correlations. PCSK9 and LDL receptor mRNA levels in flash-frozen HCC and adjacent liver tissue were determined by quantitative RT-PCR. Serum PCSK9 levels were determined by ELISA. Results: By immunohistochemistry, there was significantly lower expression of PCSK9 in HCC as compared to adjacent cirrhosis (p-value <0.0001, wilcoxon signed-rank test). Significantly greater staining of PCSK9 was present in cirrhosis compared to HCC (p value

KW - Hepatocellular carcinoma

KW - PCSK9

KW - Tumor metabolism

UR - http://www.scopus.com/inward/record.url?scp=84959162273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959162273&partnerID=8YFLogxK

U2 - 10.1186/s12876-015-0371-6

DO - 10.1186/s12876-015-0371-6

M3 - Article

C2 - 26674961

AN - SCOPUS:84959162273

VL - 15

JO - BMC Gastroenterology

JF - BMC Gastroenterology

SN - 1471-230X

IS - 1

M1 - 176

ER -